Convenient new and efficient commercial synthetic route for dasatinib (sprycel®)
| Title | Convenient new and efficient commercial synthetic route for dasatinib (sprycel®) |
| Publication Type | Journal Article |
| Year of Publication | 2017 |
| Authors | Suresh, G, Nadh, RVenkata, Srinivasu, N, Yennity, D |
| Journal | Synthetic Communications |
| Volume | 47 |
| Issue | 17 |
| Pagination | 1610-1621 |
| Date Published | JUN |
| Type of Article | Article |
| Abstract | A new and efficient synthetic route for dual Src/Abl kinase inhibitor Dasatinib (Sprycel®), an anticancer drug, is described. This commercially viable process yields Dasatinib monohydrate free of potential impurities with consistent yield of 68% in route A and 61% in route B with HPLC purity >99.80% over 4 stages. |
| DOI | 10.1080/00397911.2017.1337150 |
| Type of Journal (Indian or Foreign) | Foreign |
| Impact Factor (IF) | 1.065 |
Divison category:
Organic Chemistry
Add new comment